@article{作者manconiin6 - 2.003 = {Mauro Manconi拉斐尔·费里和马可Zucconi克劳迪奥Bassetti Stephany富尔达和路易吉Ferini-Strambi}, title ={药理离解的周期性腿部运动皮层微觉醒的不宁腿综合症(in6 - 2.003)},体积={78}={1}补充数量,页面= {in6 2.003 - 2.003——in6},年={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述周期性腿部运动之间的关系的性质在睡眠中(plm)和皮质微觉醒为了解决这一问题的临床意义和治疗plm的必要性。首页探讨药物治疗能否分离plm从皮质微觉醒通过分析氯硝西泮的微分效应或pramipexole睡眠,微觉醒,plm不宁腿综合症患者(RLS)。解决这个问题可能有关提取初步线索RLS的联合使用。背景目前,plm的病理意义和临床意义仍然是有争议的。plm的临床意义的问题的核心是plm的关系皮质和自主微觉醒。设计/方法:前瞻性、安慰剂对照、单盲、平行组研究进行了包括46个药物na{\ \我}特发性RLS患者。每个病人接受两个连续整晚障碍的研究。第一个晚上是基线的夜晚。第二晚之前,一组接受单剂量口服0.25毫克pramipexole而第二组接受单剂量口服0.5毫克的氯硝西泮,剩下的患者接受安慰剂。睡眠阶段,循环交替模式(CAP),和腿部运动活动后得分标准标准;RLS的症状也被评估。Results: Pramipexole suppressed PLMS without affecting EEG instability (CAP) and arousals (corresponding to CAP A3 and, partially, A2 subtypes), while clonazepam did the opposite, reducing the NREM sleep EEG instability without effects on PLMS. Both drugs were effective on sensitive RLS symptoms.Conclusions: This study demonstrates that a selective pharmacological approach can disconnect PLMS from arousal events, suggesting an indirect mutual relationship between each other, and opens the doors to the possibility of a joint treatment for RLS targeting sensory and motor symptoms, as well as sleep instability.Disclosure: Dr. Manconi has nothing to disclose. Dr. Ferri has nothing to disclose. Dr. Zucconi has nothing to disclose. Dr. Bassetti has nothing to disclose. Dr. Fulda has nothing to disclose. Dr. Ferini-Strambi has received personal compensation for activities with GlaxoSmithKline, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., UCB Pharma, Sanofi-Aventis Pharmaceuticals, Inc., and Pfizer Inc for activities as a scientific advisory board member. Dr. Ferini-Strambi has received personal compensation in an editorial capacity for Sleep Medicine.Monday, April 23 2012, 14:00 pm-18:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/IN6-2.003}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }